Information  X 
Enter a valid email address

Oxford Cannabinoid (OCTP)

  Print   

Wednesday 22 September, 2021

Oxford Cannabinoid

Exclusive Agreement with Canopy Growth Corporation

RNS Number : 5289M
Oxford Cannabinoid Tech.Holdings
22 September 2021
 

 

Oxford Cannabinoid Technologies Holdings plc

Exclusive Worldwide License Agreement with Canopy Growth Corporation for Key Pharmaceutical Assets

 

· Exclusive licensing agreement with leading global cannabis company ("Canopy Growth")

· Access to Canopy Growth's cannabinoid library including 335 derivatives and 14 patent families

· Accelerated timelines to clinical trials and expansion of drug development pipeline

 

Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the "Company"), the holding company of Oxford Cannabinoid Technologies Ltd ("OCT") (together, the "Group"), a company developing licensed prescription cannabinoid medicines for approval by regulatory agencies worldwide and targeting the U$ multi-billion pain market, is pleased to announce that on 21 September 2021 OCT signed an exclusive licensing agreement with Canopy Growth Corporation - a world-leading diversified cannabis and cannabinoid-based consumer product company and Tweed Inc, a wholly owned subsidiary of Canopy Growth.

 

The terms of the Agreement provide OCT with an exclusive worldwide licence to the entire cannabinoid derivative library, including 335 derivatives of cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG), intellectual property rights including 14 patent families and associated product research and development ("Canopy Library"). In return, OCT will pay Canopy Growth an annual license fee plus additional payments based on developmental, regulatory and sales milestones and royalties on future sales.

 

Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products. OCT is also responsible for the manufacture and supply of the compounds for development and commercialisation. Canopy Growth and OCT will establish a Development Steering Committee ("DSC") to monitor the progress of the development and commercialisation activities OCT is undertaking in relation to the Canopy Library.

 

The Group currently has four drug development programmes running in parallel. Its first and most advanced programme is OCT461201, which is initially targeting indications in neuropathic and visceral pain. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. OCT's second programme uses inhaled phytocannabinoids to target an undisclosed orphan pain condition, with Phase 1 trials also scheduled for Q3 2022 and Phase 2 expected in Q2 2023.

 

The Canopy Library accelerates the timelines and reduces the risks of the Group's third and fourth development programmes whilst keeping the budget and overall goals for both unchanged. The principal objective of Programme 3 is to identify a drug candidate(s) for neuropathic pain conditions. The principal objective of Programme 4 is to develop a "first-in-class" drug candidate that is expected to have use across multiple therapeutic areas including pain, neurology, immuno-inflammation and oncology.

 

Through licensing the Canopy Library, the Directors of OCTP ("Directors") believe the probability of success for Programmes 3 and 4 is significantly increased. Canopy Growth has pioneered advanced cannabinoid research, which includes the development of a library of compounds that could be relevant to the production of future cannabinoid-based products.  As Canopy Growth remains focused on commercialisation, this agreement will grant OCT access to the Canopy Library to advance this research. The Canopy Library includes compounds that have already demonstrated activity in experimental assays, including in vivo testing in mice. This further offers the potential for accelerating development of the Group's existing programmes and expanding its pipeline with additional drug development programmes.

 

The term of the agreement, on a product by product and country by country basis, is until the last to expire patent covering the relevant product or five years from first commercial sale (whichever is later) in the respective country (unless otherwise terminated); after which OCT has a perpetual, non-exclusive, fully paid-up royalty-free licence to develop, use or commercialise said product in such country. The agreement may be terminated for a material breach, insolvency or, on a category-by-category basis, in the event that OCT has ceased development of a category of compounds (e.g., the CBD, CBG or THC compounds). Both OCT and Canopy Growth give the standard indemnities, representations and warranties expected from agreements of this nature.

 

Commenting on the signing of the Agreement, OCTP Chief Executive, Dr John Lucas, said: "Acquiring an exclusive licence to Canopy Growth's pharmaceutical cannabinoid derivative library is a significant achievement for the Group and speaks volumes about our international reputation within our market.

 

"Not only does the Canopy Library provide us with over 330 "new" compounds that we can put to immediate use in our screens, we will also have an exclusive license to 14 patent families covering a wide-range of cannabinoid derivatives. We believe this will increase the probability of a favourable outcome from Programmes 3 and 4 and accelerate the timeframe to clinical trials. Importantly, the library offers the opportunity to develop additional drug development programmes that should expand our drug development pipeline."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

 

The Directors of the Company accept responsibility for the content of this announcement.

 

Enquiries:

Oxford Cannabinoid Technologies Holdings plc

Dr John Lucas (CEO)

Clarissa Sowemimo-Coker (COO)

 

+44 (0)20 3034 2820

[email protected]

[email protected]

Cairn Financial Advisers

Emily Staples

Jo Turner

 

 

+44 (0)20 7213 0897

+44 (0) 20 7213 0885

Walbrook PR Limited

Paul Vann

Nicholas Johnson

 

+44 (0)20 7933 8780

+44 (0)7768 807631

[email protected]

 

Canopy Growth Corporation

Jennifer White

 

[email protected]

 

 

About Oxford Cannabinoid Technologies Holdings Plc :

 

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market (together the "Group"). Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth. The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.

 

The Group's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group's lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022. The Group's product pipeline also uses a balanced drug product strategy that employs phytocannabinoids, cannabinoid derivatives and other novel compounds for the treatment of pain.

 

OCTP operates a partnership model with external academic and commercial partners, including the University of Oxford.

 

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

About Canopy Growth Corporation

 

Canopy Growth (TSX:WEED,NASDAQ: CGC ) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Canopy Growth offers product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices. Canopy Growth's global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional hemp-derived CBD products to the United States through its First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRPPUGABUPGPPG

a d v e r t i s e m e n t